PharmaLab 2019 – In times of changes
For the 7th time, PharmaLab, picks up the latest developments in regulations, quality control and assurance and in laboratory methods and systems.
List view / Grid view
For the 7th time, PharmaLab, picks up the latest developments in regulations, quality control and assurance and in laboratory methods and systems.
The pharmaceutical company Roche has affirmed that it was hit by a Winnti cyber-attack, thought to be supported by the Chinese government.
Two lots of Kogenate® FS vials actually contain the FVIII hemophilia A treatment, Jivi®.
The FDA has announced that it has granted approval to the first nine generic drug applications for Pfizer’s Lyrica treatment.
The FDA has handed a CRL to Biohaven for its ALS treatment awaiting approval due to concerns regarding the medication’s API.
An Indian pharmaceutical company was planning to shred quality control records ahead of an FDA inspection, found officials.
Altaire Pharmaceuticals has announced a recall of 31 products due to a lack of sterility assurance from their manufacturing facility.
Genotoxic impurities (GTI’s) are intermediate, reactive products or degradants formed during drug synthesis, formulation or storage.
A medical centre in Hong Kong had 76 boxes of an HPV vaccine seized after a complaint from a patient who experienced adverse side effects.
A pharmaceutical manufacturing site in New Jersey receives FDA warning letter for failing to thoroughly investigate quality problems and data integrity issues.
The FDA and EMA have agreed to rely on each other’s assessment of pharmaceutical manufacturing sites to reduce duplicative work.
The 34th and, so far, biggest edition of Chemspec Europe attracted a total of 4,295 trade visitors from 53 countries to the exhibition grounds of Messe Basel, Switzerland. From 26 to 27 June 2019, a total of 379 exhibitors from 27 countries presented their innovative substances on a record net…
Comparison of the Sartorius Claristep Filtration System with standard sample preparation using syringe filters.
Three API re-packers who failed to meet current good manufacturing practice requirements have received warning letters from the FDA.
Substandard and counterfeit drugs can negatively impact the pharmaceutical industry and patients. Here, we investigate counterfeits in south-east Asia and possible solutions.